Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
International Journal of Medicinal Mushrooms
Импакт фактор: 1.423 5-летний Импакт фактор: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN Печать: 1521-9437
ISSN Онлайн: 1940-4344

Выпуски:
Том 22, 2020 Том 21, 2019 Том 20, 2018 Том 19, 2017 Том 18, 2016 Том 17, 2015 Том 16, 2014 Том 15, 2013 Том 14, 2012 Том 13, 2011 Том 12, 2010 Том 11, 2009 Том 10, 2008 Том 9, 2007 Том 8, 2006 Том 7, 2005 Том 6, 2004 Том 5, 2003 Том 4, 2002 Том 3, 2001 Том 2, 2000 Том 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v6.i4.30
8 pages

A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease

Yihuai Gao
Institute of Food, Nutrition and Human Health, Massey University; Landcare Research, Private Bag 92170, Auckland, New Zealand
Guoliang Chen
Division of Traditional Chinese Medicine, New Zealand Institute of Natural Medicines, Auckland, New Zealand
Xihu Dai
Department of Internal Medicine, Fuzhou General Hospital of Nanjing Military Region of the Peoples' Liberation Army, Fuzhou, R.P. China
Jingxian Ye
Department of Integrated Medicine. Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, R.P. China
Shufeng Zhou
Division of Pharmacy, School of Life Sciences, Faculty of Science, Queensland University of Technology, Australia; Department of Pharmacy, Faculty of Science, National University of Singapore; University of South Florida FL 33612, USA

Краткое описание

The polysaccharides and triterpenes isolated from Ganoderma lucidum have shown hypolipidemic, hypotensive, and antithrombotic effects. This double-blind, randomized, multicentered study was designed to evaluate the clinical effects and safety of extracted G. lucidum polysaccharides (Ganopoly) in patients with confirmed coronary heart disease (CHD). Patients were randomly assigned to receive Ganopoly (n = 88) or placebo (n = 82) for 12 weeks. Effects of therapy on improvement of major symptoms, electrocardiogram (ECG) changes, and serum cholesterol level were investigated. Ten patients were lost to the trial, leaving 80 in each group to be assessed after 12 weeks. The results indicate that patients in both groups were similar with respect to age, gender, serum cholesterol level, and disease duration. Ganopoly treatment gave a significantly higher improved percentage (31.6−54.7%) of the primary symptoms (chest pain, palpitation, angina pectoris, and shortness of breath) in CHD patients compared to the control group (17.2−24.7%). The percentage of abnormal ECG also significantly decreased from 74 to 55% in the treatment group, compared to a decrease of 76 to 74% in the control group. Ganopoly treatment also resulted in a significant decrease of blood pressure, whereas control group did not. The diastolic pressure was decreased by ≥10 mmHg in 22.5% patients receiving Ganopoly. The average blood pressure (systolic/diastolic, 142.5/96.4 mmHg) in this group was reduced to 135.1/92.8 mmHg after 12 weeks of treatment. Serum cholesterol levels decreased significantly after 12 weeks of Ganopoly therapy to the baseline values, whereas cholesterol levels remained unchanged in the control group. Ganopoly is well tolerated and appeared to be active in patients with CHD.